SCHEDULE 13G/A: Janus Henderson Group Discloses 6.2% Passive Stake in CARGO Therapeutics

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a 6.2% beneficial ownership stake in CARGO Therapeutics, Inc. as of December 31, 2024.

Summary

• Janus Henderson Group plc, an investment adviser and holding company, filed an Amendment No. 2 to its Schedule 13G regarding its beneficial ownership in CARGO Therapeutics, Inc.
• As of December 31, 2024, Janus Henderson Group plc beneficially owns an aggregate of 2,830,544 shares of CARGO Therapeutics, Inc. Common Stock.
• This ownership represents 6.2% of the total class of CARGO Therapeutics, Inc. Common Stock.
• The shares are held with shared voting power and shared dispositive power.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual, routine regulatory filing disclosing beneficial ownership and does not contain information that would inherently convey positive or negative sentiment regarding the issuer's performance or outlook.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of an institutional investor's passive ownership stake and does not provide specific insights into broader industry trends or CARGO Therapeutics' competitive position.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's passive stake, which can be viewed as a vote of confidence in the company's long-term prospects by a major fund.
• Company Management: Awareness of a significant passive shareholder, though no direct influence on control is intended or stated by the reporting person.

Key Dates

Keywords

CARGO Therapeutics, Janus Henderson Group, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Holding Company, SEC Filing, Passive Investment